JOUNCE THERAPEUTICS INC

Jounce Therapeutics, Inc. (http://jouncetx.com/) is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. It focuses on specific cell types, both immune and non-immune, within tumors, and targets and identifies related biomarkers designed to match the right therapy to the right patient. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). It also develops JTX-1811, a monoclonal antibody targeting CCR8.

• JOUNCE THERAPEUTICS INC